HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajendran, J. G. Articles by Fritzberg, A. Search for Related Content PubMed PubMed Citation Articles by Rajendran, J. G. Articles by Fritzberg, A.

High-Dose ¹⁶⁶Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation

¹ Department of Radiology, University of Washington, Seattle, Washington
² Fred Hutchinson Cancer Research Center, Seattle, Washington
³ NeoRx Corporation, Seattle, Washington

View larger version (12K): [in a new window]   FIGURE 1. 166Ho-DOTMP serum disappearance after test dose.

View larger version (13K): [in a new window]   FIGURE 2. 166Ho-DOTMP serum disappearance after therapy dose.

View larger version (11K): [in a new window]   FIGURE 3. 166Ho-DOTMP serum disappearance: test dose vs. therapy dose for 2 patients.

View larger version (16K): [in a new window]   FIGURE 4. Cumulative urinary excretion of 166Ho-DOTMP after test dose.

View larger version (9K): [in a new window]   FIGURE 5. 166Ho-DOTMP whole-body patient residence curves derived from whole-body counts obtained using NaI probe.

View larger version (119K): [in a new window]   FIGURE 6. 166Ho-DOTMP whole-body gamma camera images (anterior [left] and posterior [right]) obtained at 19 h after test dose.